Australia markets close in 4 hours 16 minutes

CSPC Innovation Pharmaceutical Co., Ltd. (300765.SZ)

Shenzhen - Shenzhen Delayed price. Currency in CNY
Add to watchlist
29.69-0.01 (-0.03%)
As of 09:41AM CST. Market open.
Currency in CNY

Valuation measures4

Market cap (intra-day) 41.72B
Enterprise value 39.03B
Trailing P/E 58.68
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)17.98
Price/book (mrq)9.46
Enterprise value/revenue 16.92
Enterprise value/EBITDA 46.64

Trading information

Stock price history

Beta (5Y monthly) -0.25
52-week change 3175.43%
S&P500 52-week change 323.76%
52-week high 340.62
52-week low 39.09
50-day moving average 331.70
200-day moving average 327.07

Share statistics

Avg vol (3-month) 311.51M
Avg vol (10-day) 311.02M
Shares outstanding 51.4B
Implied shares outstanding 61.45B
Float 8348.23M
% held by insiders 177.29%
% held by institutions 13.13%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.32
Forward annual dividend yield 41.08%
Trailing annual dividend rate 30.27
Trailing annual dividend yield 30.90%
5-year average dividend yield 4N/A
Payout ratio 424.70%
Dividend date 3N/A
Ex-dividend date 425 Apr 2024
Last split factor 21.2:1
Last split date 325 Apr 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 30.57%
Operating margin (ttm)8.30%

Management effectiveness

Return on assets (ttm)7.51%
Return on equity (ttm)14.00%

Income statement

Revenue (ttm)2.31B
Revenue per share (ttm)1.65
Quarterly revenue growth (yoy)-27.10%
Gross profit (ttm)N/A
EBITDA 805.49M
Net income avi to common (ttm)705.32M
Diluted EPS (ttm)0.50
Quarterly earnings growth (yoy)-38.90%

Balance sheet

Total cash (mrq)2.69B
Total cash per share (mrq)1.91
Total debt (mrq)1.45M
Total debt/equity (mrq)0.03%
Current ratio (mrq)3.91
Book value per share (mrq)3.14

Cash flow statement

Operating cash flow (ttm)-344.33M
Levered free cash flow (ttm)960.3M